Literature DB >> 21161617

Quality of care in patients with gout: why is management suboptimal and what can be done about it?

N Lawrence Edwards1.   

Abstract

Gout is a common inflammatory arthritis. We know a great deal about its etiopathogenesis and have relatively safe and effective therapies for it. Gout, however, remains a poorly managed disease with mistakes made in securing an accurate diagnosis and in using appropriate therapies for acute and chronic stages of the disease. Synovial fluid analysis with polarizing microscopy is the "gold standard" for confirming the diagnosis of gout but has been used in fewer than 10% of all patients diagnosed with gout. The newly adopted European clinical guidelines offer a practical alternative to synovial fluid analysis, but primary care physicians are not well-versed in their use. Other serious errors in the management of gout are related to the use of medications to treat acute and chronic gout. Frequently, the anti-inflammatory drugs used to treat acute symptoms and urate-lowering drugs used to prevent long-term destruction are improperly dosed, leading to dissatisfaction on the part of patients and physicians. Widespread education about evidence-based diagnostic and treatment guidelines is desperately needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21161617     DOI: 10.1007/s11926-010-0154-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  30 in total

Review 1.  How well have diagnostic tests and therapies for gout been evaluated?

Authors:  N Schlesinger; D G Baker; H R Schumacher
Journal:  Curr Opin Rheumatol       Date:  1999-09       Impact factor: 5.006

2.  How is gout managed in primary care? A review of current practice and proposed guidelines.

Authors:  B Pal; M Foxall; T Dysart; F Carey; M Whittaker
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

3.  Identification of urate crystals in gouty synovial fluid.

Authors:  D J MCCARTY; J L HOLLANDER
Journal:  Ann Intern Med       Date:  1961-03       Impact factor: 25.391

Review 4.  Quality of care indicators for gout management.

Authors:  Ted R Mikuls; Catherine H MacLean; Jason Olivieri; Fausto Patino; Jeroan J Allison; John T Farrar; Warren B Bilker; Kenneth G Saag
Journal:  Arthritis Rheum       Date:  2004-03

Review 5.  Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

Authors:  Fernando Perez-Ruiz; Frédéric Lioté
Journal:  Arthritis Rheum       Date:  2007-10-15

6.  Sex differences in gout epidemiology: evaluation and treatment.

Authors:  L R Harrold; R A Yood; T R Mikuls; S E Andrade; J Davis; J Fuller; K A Chan; D Roblin; M A Raebel; A Von Worley; R Platt; K G Saag
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

7.  Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

Authors:  T R Mikuls; J T Farrar; W B Bilker; S Fernandes; K G Saag
Journal:  Rheumatology (Oxford)       Date:  2005-05-03       Impact factor: 7.580

8.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

9.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Authors:  F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

Review 10.  Update on gout: new therapeutic strategies and options.

Authors:  Robert Terkeltaub
Journal:  Nat Rev Rheumatol       Date:  2010-01       Impact factor: 20.543

View more
  20 in total

1.  A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial.

Authors:  Robert Goldfien; Alice Pressman; Alice Jacobson; Michele Ng; Andrew Avins
Journal:  Perm J       Date:  2016-07-01

2.  [Diagnosis and management of gout in Austria. Survey of current practice considering the EULAR recommendations].

Authors:  J Sautner
Journal:  Z Rheumatol       Date:  2014-11       Impact factor: 1.372

Review 3.  Gout and Metabolic Syndrome: a Tangled Web.

Authors:  Gabrielle E Thottam; Svetlana Krasnokutsky; Michael H Pillinger
Journal:  Curr Rheumatol Rep       Date:  2017-08-26       Impact factor: 4.592

4.  The Pyroptotic Cell Death Effector Gasdermin D Is Activated by Gout-Associated Uric Acid Crystals but Is Dispensable for Cell Death and IL-1β Release.

Authors:  Maryam Rashidi; Daniel S Simpson; Anne Hempel; Daniel Frank; Emma Petrie; Angelina Vince; Rebecca Feltham; Jane Murphy; Simon M Chatfield; Guy S Salvesen; James M Murphy; Ian P Wicks; James E Vince
Journal:  J Immunol       Date:  2019-06-17       Impact factor: 5.422

Review 5.  Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.

Authors:  Allison Guttmann; Svetlana Krasnokutsky; Michael H Pillinger; Adey Berhanu
Journal:  Ther Adv Drug Saf       Date:  2017-09-13

6.  eHealth-supported decentralized multi-disciplinary care for gout involving rheumatology, pharmacy, and dietetics: proof-of-concept study.

Authors:  Alyssa Howren; Nicole W Tsao; Hyon K Choi; Kam Shojania; Alison Kydd; Russell Friesen; J Antonio Avina-Zubieta; Mary A De Vera
Journal:  Clin Rheumatol       Date:  2019-11-13       Impact factor: 2.980

7.  Gout treatment: survey of Brazilian rheumatology residents.

Authors:  Rodrigo Balbino Chaves Amorim; Ana Beatriz Vargas-Santos; Leticia Rocha Pereira; Evandro Silva Freire Coutinho; Geraldo da Rocha Castelar-Pinheiro
Journal:  Clin Rheumatol       Date:  2017-01-19       Impact factor: 2.980

Review 8.  The patient's experience of gout: new insights to optimize management.

Authors:  Nicola Dalbeth; Karen Lindsay
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

9.  Goals of gout treatment: a patient perspective.

Authors:  Jasvinder A Singh
Journal:  Clin Rheumatol       Date:  2018-08-04       Impact factor: 2.980

10.  Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011.

Authors:  Sharan K Rai; J Antonio Aviña-Zubieta; Natalie McCormick; Mary A De Vera; Diane Lacaille; Eric C Sayre; Hyon K Choi
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-05       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.